Jörn Schattenberg รีทวีตแล้ว

The closing Plenary of Day 2 at #SLDSummit 2026 is focused on the next wave of therapeutic development in SLD.
Metabolic directed and liver directed treatment strategies are being examined in depth, reflecting the rapidly expanding pipeline of potential interventions. Fresh data on metabolic modulation in MASLD and type 2 diabetes are contributing to the evolving evidence base.
The discussion is also tackling a key question in cirrhosis care, whether treatment goals should prioritise fibrosis regression or tangible clinical outcomes. A forward thinking exchange is setting the tone as we head into the final day of the Summit.
@schattenbergJ

English




































